Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cymabay Therapeutics (CBAY)

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 441,702
  • Shares Outstanding, K 68,694
  • Annual Sales, $ 0 K
  • Annual Income, $ -72,550 K
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.37
  • Number of Estimates 8
  • High Estimate -0.34
  • Low Estimate -0.41
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -23.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.16 +1.06%
on 07/18/19
7.36 -15.49%
on 07/01/19
-0.80 (-11.40%)
since 06/19/19
3-Month
4.82 +29.05%
on 06/11/19
13.55 -54.10%
on 04/30/19
-5.85 (-48.47%)
since 04/18/19
52-Week
4.82 +29.05%
on 06/11/19
14.00 -55.57%
on 03/05/19
-6.58 (-51.41%)
since 07/19/18

Most Recent Stories

More News
Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock

CymaBay Therapeutics (CBAY) needs investors to pay close attention to the stock based on moves in the options market lately.

CBAY : 6.22 (-3.27%)
CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial...

CBAY : 6.22 (-3.27%)
CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the treatment of primary biliary cholangitis (PBC) will be...

CBAY : 6.22 (-3.27%)
CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress(TM) 2019

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced...

CBAY : 6.22 (-3.27%)
PPAR-Beta / Delta Agonist Pipeline Insights, 2019 Report Featuring Genfit, CymaBay Therapeutics, Inventiva Pharma, Chipscreen Biosciences, & Senju Pharmaceutical - ResearchAndMarkets.com

The "PPAR-Beta / Delta Agonist -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

CBAY : 6.22 (-3.27%)
GNFTF : 19.5300 (+5.74%)
CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference(TM) 2019

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver Congress of the European Association for the Study of Liver...

CBAY : 6.22 (-3.27%)
Market Trends Toward New Normal in Louisiana-Pacific, The Michaels Companies, VEREIT, CymaBay Therapeutics, CareDx, and Harsco -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Louisiana-Pacific Corporation...

VER : 8.82 (-1.89%)
LPX : 26.03 (-0.08%)
CBAY : 6.22 (-3.27%)
HSC : 25.07 (+0.52%)
CDNA : 31.72 (+0.13%)
MIK : 7.81 (-6.69%)
CymaBay Therapeutics to Present at Upcoming Investor Conferences in March

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 6.22 (-3.27%)
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 6.22 (-3.27%)
CymaBay Announces Pricing of Public Offering of Common Stock

CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 6.22 (-3.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CBAY with:

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Key Turning Points

2nd Resistance Point 6.59
1st Resistance Point 6.41
Last Price 6.22
1st Support Level 6.11
2nd Support Level 5.99

See More

52-Week High 14.00
Fibonacci 61.8% 10.49
Fibonacci 50% 9.41
Fibonacci 38.2% 8.33
Last Price 6.22
52-Week Low 4.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar